Pannexin-2 (PANX2)

Pannexin-2 (PANX2) is a member of the pannexin family of transmembrane channel proteins homologous to innexins, traditionally associated with gap junctions but primarily forming non-junctional plasma membrane channels in vertebrates[1][2][4][8]. PANX2 is a heptameric ion channel with a four-transmembrane domain structure that forms a non-selective, ATP-permeable pore involved in the regulation of ATP release, ionic exchange, and cellular signaling[1][5][6]. It has a distinct selectivity filter and anion permeability properties that differ from PANX1 and resemble those of the volume-regulated anion channel LRRC8A[6][2]. PANX2 is ubiquitously expressed, with noted roles in neuronal development, skin homeostasis, apoptosis, and cellular responses to stress like ischemia and UV irradiation[3][7]. Dysregulation of PANX2 is implicated in various diseases, including gliomas (where higher expression correlates with better prognosis)[1][3], ischemic brain injury, neurodegeneration, prostate cancer, and diabetes (through pancreatic β-cell apoptosis)[3]. While DCPIB is reported as a channel inhibitor, it is not PANX2-specific and also inhibits other anion channels, highlighting a need for more selective modulators[2][6]. PANX2's role in disease and physiology makes it a considered but complex therapeutic target, with challenges stemming from its broad tissue distribution and non-specific pharmacological tools[6][7].

Other names

Pannexin 2PANX2hPANX2PX2pannexin-2

Channel inhibition (anion channel blockade, as with DCPIB)